Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects.
Biolex will retain all development and commercialization rights to the humanized antibody, and Medical Research Council Technology (MRCT) will receive regulatory milestone payments and royalties upon its successful development.
Jan Turek, president & CEO of Biolex, said: “Applying the glycosylation optimization capabilities of our LEX System to a humanized antibody provides the potential for a next-generation product that offers a therapeutic advantage while also addressing the relatively low potency and problematic side-effect burden of the current standard of care.”